Glenmark arm gets Russian Health Ministry nod for nasal spray Ryaltris

Press Trust of India New Delhi | Updated on February 22, 2021 Published on February 22, 2021

Glenmark Pharmaceuticals on Monday said its Swiss subsidiary has received marketing approval from the Russian health regulator for its nasal spray Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

“Glenmark Specialty received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris Nasal Spray — a novel fixed-dose combination nasal spray. This paves the way for commercialisation of Ryaltris in Russia which is expected to be made available to patients in the country in Q1FY2021-22,” Glenmark Pharmaceuticals said in a regulatory filing.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent. Allergic rhinitis can impact a person’s quality of life and lead to functional impairments, as well as increase the risk of having asthma, the company said.

Csaba Kantor, Senior Vice-President - Russia and CIS region, Glenmark Pharmaceuticals, said Russia is one of the key markets for the company and it consistently looking to expand its product portfolio.

“Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally... This new innovative addition to our portfolio is yet another major step in strengthening Glenmark’s respiratory focus in Russia and the CIS region,” Kantor added.

Shares of Glenmark Pharmaceuticals were trading 0.18 per cent higher at ₹483.25 apiece on BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 22, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.